Skip to main content

Akkaraju Srinivas's Form 4 filing

Kalaris Therapeutics, Inc. (KLRS) · filed May 22, 2026

Accession no.
0001231919-26-000532
Filed
May 22, 2026, 7:47 PM ET
Trade date
May 20, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions. Open-market purchases total $1.18M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Akkaraju SrinivasCIK 0001253170Director, 10% Owner
Samsara BioCapital, L.P.CIK 000169973710% Owner
Samsara BioCapital GP, LLCCIK 000188882910% Owner
Samsara Opportunity Fund, L.P.CIK 000208619310% Owner
Samsara Opportunity Fund GP, LLCCIK 000208645610% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 20, 2026Common StockPPurchaseAcquired+244,300$4.83+$1,179,9692,224,147Indirect
May 20, 2026Common StockJOtherDisposed−66,906$0.00$010,657,028Indirect
May 20, 2026Common StockJOtherAcquired+14,937$0.00$014,937Indirect
May 20, 2026Common StockJOtherAcquired+4,471$0.00$019,408Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)